XM does not provide services to residents of the United States of America.
N
N

Nestle

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Nestle, Coke take cautious approach to catering to Ozempic users

UPDATE 1-FOCUS-Nestle, Coke take cautious approach to catering to Ozempic users Adds Coca-Cola, Herbalife comment, paragraphs 18, 23 By Jessica DiNapoli NEW YORK, June 20 (Reuters) - Nestle's NESN.S new food brand for people taking weight-loss drugs like Wegovy will note that the meals are high in protein, fiber and nutrients, but will not name the blockbuster medications, a company executive told Reuters.
D
N
C

Nestle, Coke, Danone take cautious approach to catering to Ozempic users

FOCUS-Nestle, Coke, Danone take cautious approach to catering to Ozempic users Updates headline, no changes to text By Jessica DiNapoli NEW YORK, June 20 (Reuters) - Nestle's NESN.S new food brand for people taking weight-loss drugs like Wegovy will note that the meals are high in protein, fiber and nutrients, but will not name the blockbuster medications, a company executive told Reuters.
D
N
C

Food companies with Ozempic-friendly snacks and meals wade carefully into weight-loss waters

FOCUS-Food companies with Ozempic-friendly snacks and meals wade carefully into weight-loss waters By Jessica DiNapoli NEW YORK, June 20 (Reuters) - Nestle's NESN.S new food brand for people taking weight-loss drugs like Wegovy will note that the meals are high in protein, fiber and nutrients, but will not name the blockbuster medications, a company executive told Reuters.
D
N
C

Givaudan, National Grid, Schneider Electric

EUROPE RESEARCH ROUNDUP-Givaudan, National Grid, Schneider Electric June 18 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Givaudan, National Grid and Schneider Electric, on Tuesday. HIGHLIGHTS * Crest Nicholson Holdings Plc CRST.L : RBC raises target price to 250p from 175p * Givaudan SA GIVN.S : JP Morgan raises target price to CHF 4,200 from CHF 3,800 * National Grid NG.L : Barclays cuts target price to 1120p from 1365p * Schne
A
B
C
C
E
G
G
H
H
H
I
I
L
L
N
P
S
S
S
H
A
A
N
S
S
W

Hyundai’s India IPO will have imitators

RPT-BREAKINGVIEWS-Hyundai’s India IPO will have imitators Corrects to fix sourcing in the second paragraph. The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Refiles to add hyperlink. By Shritama Bose MUMBAI, June 17 (Reuters Breakingviews) - If Hyundai Motor's 005380.KS up to $3 billion initial public offering of its Indian business crystallises a premium valuation as easily as expected, other multinationals could rush to list their local operations in the S
B
H
J
N
P
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.